Skip header and navigation

1 records – page 1 of 1.

Azathioprine and Mercaptopurine Therapy

https://libcat.nshealth.ca/en/permalink/chpams35565
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1079
Available Online
View Pamphlet
This pamphlet will help you decide if azathioprine (ImuranĀ®) or mercaptopurine therapy is right for you. The pamphlet explains what azathioprine (AZA) and mercaptopurine (6-MP) are, how well they work, as well as serious and less serious side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative Inflammatory Bowel Disease Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (6 p.): digital, PDF file
Subjects (MeSH)
Immunosuppressive Agents
Azathioprine
Mercaptopurine
Subjects (LCSH)
Immunosuppressive agents
Specialty
Medications
Abstract
This pamphlet will help you decide if azathioprine (Imuran®) or mercaptopurine therapy is right for you. The pamphlet explains what azathioprine (AZA) and mercaptopurine (6-MP) are, how well they work, as well as serious and less serious side-effects. The pamphlet also includes a list of what you can do to lower the chances of side-effects.
Notes
Previous title: Azathioprine (Imuran) therapy
Responsibility
Prepared by: Nova Scotia Collaborative Inflammatory Bowel Disease Program
Pamphlet Number
1079
Less detail